KELOWNA, BRITISH COLUMBIA--(MARKET WIRE)--Jul 30, 2007 -- Sernova Corp. (CDNX:SVA.V - News), a company focused on a novel treatment for insulin-dependent diabetes using its Sertolin cell technology, is pleased to announce it has filed a patent application for the therapeutic use of adult Sertoli cells. Compared to the standard juvenile cells, adult Sertoli cells have enhanced protective properties that are particularly effective at protecting co-transplanted cells from being destroyed by the body’s immune system.